Videos

ARANOTE TE

Search

ARANOTE Trial Implications for Metastatic Prostate Cancer Management, Journal Club - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen discuss the ARANOTE trial, a phase III study evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. They highlight the trial's design, which randomized 669 patients to darolutamide plus ADT or placebo plus ADT. The study meets its primary endpoint, showing significant improvement in radiographic progression-free survival for the darolutami...
Advancing mHSPC Treatment Options: ARANOTE Trial Analysis - Neal Shore & Fred Saad Details Fred Saad and Neal Shore discuss the ARANOTE trial with Zach Klaassen, exploring the use of darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. They highlight the trial's diverse patient population and impressive results, including a 46% reduction in radiographic progression-free survival risk. The conversation covers the efficacy of this doublet therapy in various subgroups, pa...
Darolutamide Improves Outcomes for mHSPC Patients in ARANOTE Trial - Fred Saad Details Neeraj Agarwal interviews Fred Saad about the Phase III ARANOTE trial. The study investigates darolutamide plus ADT versus placebo plus ADT in metastatic hormone-sensitive prostate cancer. Dr. Saad discusses the trial's design, patient demographics, and key findings. The results show significant improvements in radiographic progression-free survival, time to mCRPC, pain progression, and PSA respon...
ARANOTE Study: Transforming Metastatic Hormone Sensitive Prostate Cancer Treatment - Fred Saad Details Fred Saad discusses the ARANOTE phase 3 study results, evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. The trial shows significant improvement in radiographic progression-free survival and secondary endpoints, including time to metastatic CRPC and pain progression. Dr. Saad emphasizes the favorable safety profile of darolutamide, with adverse events similar to pla...
Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore Details Neal Shore discusses the ARASENS trial's post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment strateg...
ARANOTE - Darolutamide in Addition to ADT Vs. ADT in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) - Fred Saad Details Alicia Morgans and Fred Saad discuss the ongoing ARANOTE trial, assessing darolutamide and androgen deprivation therapy (ADT), as compared to ADT alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC). ARANOTE is an international, multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Dr. Saad gives a background on the trial. Biographies: Fred Saad, MD, FRCS...